Daily Medication Pearl: Maralixibat (Livmarli)

Article

Maralixibat (Livmarli) is an ileal bile acid transporter inhibitor indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.

Medication Pearl of the Day: Maralixibat (Livmarli)

Indication: Maralixibat (Livmarli) is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.

Insight:

  • Dosing:The recommended dosage is 380 mcg/kg once daily, taken 30 minutes before the first meal of the day.
  • Dosage forms: Oral solution 9.5 mg of maralixibat per mL.
  • Adverse events: Most common adverse reactions (≥5%) are diarrhea, abdominal pain, vomiting, fat-soluble vitamin deficiency, liver test abnormalities, gastrointestinal bleeding, and bone fractures.
  • Mechanism of action: Maralixibat is a reversible inhibitor of IBAT. It decreases the reabsorption of bile acids (primarily the salt forms) from the terminal ileum.
  • Manufacturer: Mirum Pharmaceuticals

Source

prescribinginformation.pdf (mirumpharma.com)

Related Videos
Female Pharmacist Holding Tablet PC - Image credit: Tyler Olson | stock.adobe.com
African American male pharmacist using digital tablet during inventory in pharmacy - Image credit: sofiko14 | stock.adobe.com
palliative and hospice care/ Image Credits: © David Pereiras - stock.adobe.com
Young woman using smart phone,Social media concept. - Image credit: Urupong | stock.adobe.com
multiple myeloma clinical trial daratumumab/ Image Credits: © Dragana Gordic - stock.adobe.com
multiple myeloma clinical trial/Image Credits: © Studio Romantic - stock.adobe.com
selling mental health medication to man at pharmacy | Image Credit: Syda Productions - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.